Contact Us Advertise Events
The Microbiome Business & Science Briefing
Microbi meTimes
Reporting on The Latest Microbiome Business & Scientific Developments
  • Research
  • Clinical & Manufacturing
  • Finance
  • Gastrointestinal
  • GMO & Synbio
  • Gut-Brain Axis
  • Infectious Disease & AMR
  • Oncology
  • Biotics and Supplements
  • Regulatory & Policy
  • Skin Health
  • Women’s Health
    • TRENDING
    MRM Health and Biocodex Establish Strategic Partnership to Strengthen Future Commercial Supply Capabilities for CORAL®-Based Medicines• Beyond the small intestine: ileo colonic delivery as the next frontier for oral therapeutics• Scientists Call for a National Microbiome “Moonshot” to Tackle Chronic Disease• The Oral Delivery Challenge: Why It Requires More Than the Right Route• Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets• Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• MRM Health and Biocodex Establish Strategic Partnership to Strengthen Future Commercial Supply Capabilities for CORAL®-Based Medicines• Beyond the small intestine: ileo colonic delivery as the next frontier for oral therapeutics• Scientists Call for a National Microbiome “Moonshot” to Tackle Chronic Disease• The Oral Delivery Challenge: Why It Requires More Than the Right Route• Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets• Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development•
    Editor's Choice /Pharma & Human Health
    Editor's Choice

    Interview with Jim Weston and Stephen Conafay of the MTIG

    BY Kristina Campbell · SEP 22, 2019 · 1 MIN READ
    in X ✉
    Kristina Campbell

    Microbiome Science Writer <a href="https://www.microbiometimes.com">The Microbiome Times</a>  

    Related Coverage
    Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment
    Editor's Choice

    Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment

    SEP 28, 2026
    A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation
    Editor's Choice

    A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation

    SEP 1, 2026
    Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?
    Editor's Choice

    Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?

    AUG 10, 2026

    Sign up to our free newsletter

    The science, the funding, and the regulation — in your inbox.

    Most Read This Week

    • 1
      Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health
    • 2
      MRM Health and Biocodex Establish Strategic Partnership to Strengthen Future Commercial Supply Capabilities for CORAL®-Based Medicines
    • 3
      THE ROLE OF BIOFILMS: An Interview with Scioto Biosciences
    • 4
      Vedanta Biosciences Receives Award from the Crohn’s & Colitis Foundation to Advance a Microbiome-Derived Therapeutic Program for Interception and Treatment of Inflammatory Bowel Disease
    • 5
      Scientists Call for a National Microbiome “Moonshot” to Tackle Chronic Disease

    NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS:

    Microbiome Times Magazine

    Reporting on The Latest Microbiome Business & Scientific Developments

    Sections
    • Pharma & Human Health
    • Finance
    • Research
    • Editor's Choice
    Company
    • Issue Archive
    Business
    • Advertise
    Stay Connected
    • LinkedIn
    • Contact
    © 2026 Microbiome Times Magazine
    Microbiome Times Forum USA

    Meet Your Next Collaborator

    San Francisco  •  October 21–22, 2026

    400+ biotech leaders, VCs and researchers gather for two days of partnering and dealmaking in the microbiome space. Free to attend for start-ups, academic innovators, investors and healthcare organisations.

    View the Program Register Free →